Since 2016, CARB-X has awarded $452 million for early-stage development of antibacterials and other products targeting drug-resistant bacteria.
Overall pooled VE was 39% in preventing flu-associated outpatient visits.
The latest round of free at-home tests began in November 2023 heading into the winter respiratory virus season.
Michigan has reported 2 more cases from 2 different counties, part of a small but steady rise in US cases.
Transmission appears to be low, but health officials are monitoring the variant because of potential immune escape.
The mechanisms for the menstrual changes, which the authors say are usually not clinically significant, may have to do with the immune response to vaccines.
The observed median time to first recovery was 14 days in the ivermectin group and 15 in the usual-care group.
The authors found strong evidence of viral circulation before initial case detection in each affected world region.
The patients had both consumed potentially contaminated raw date palm sap, a known risk factor for contracting the virus.
The report calls for progress in 4 key areas: antibiotic manufacturing, antibiotic research and development, access, and appropriate use.
Danish research and development company GlyProVac will receive $467,000 to develop a maternal vaccine that targets a leading cause of neonatal sepsis.
Dengue cases in the Americas so far this year are outpacing last year's record activity.
For the first time, the mid-season report from four VE networks covers both pediatric and adult age groups.
Of the 135 isolates, 55% were identified as containing multi-drug resistant E coli.
Researchers saw sustained efficacy against both severe and less severe symptoms.
Patients undergoing gastrointestinal surgery at safety net hospitals had a nearly 30% increased risk of SSIs compared with all hospitals.
The recommendation applies to people traveling to outbreak areas and others at extra risk from the virus.
There was also a lower 3-month mortality (31% vs 39%) for the antiplatelet-therapy group.
The first-in-class, novel antibiotic showed non-inferiority to the current standard-of-care gonorrhea treatment.
A systematic review and meta-analysis found that women with Staphylococcus aureus bacteremia had an 18% increased mortality risk compared with men.
The step frees up more resources for the dengue outbreak, which has sickened more than 31,000 people so far.
Several factors may be contributing to the increase, including the El Nino weather pattern and climate change effects.
Gonorrhea is one of the most common sexually transmitted infections, with more than 82 million people diagnosed annually.
While the FDA did not identify clinical safety or efficacy issues with the combination antibiotic, it asked for more information about manufacturing processes.
A report from the GLG includes 6 recommendations aimed at incentivizing innovation, stimulating R&D efforts, and ensuring access to antibiotics.